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Abstract 
Background: We introduce and demonstrate that the AC biosusceptometry (ACB) technique enables real‑time 
monitoring of magnetic nanoparticles (MNPs) in the bloodstream. We present an ACB system as a simple, portable, 
versatile, non‑invasive, and accessible tool to study pharmacokinetic parameters of MNPs, such as circulation time, in 
real time. We synthesized and monitored manganese doped iron oxide nanoparticles in the bloodstream of Wistar 
rats using two different injection protocols. Aiming towards a translational approach, we also simultaneously evalu‑
ated cardiovascular parameters, including mean arterial pressure, heart rate, and episodes of arrhythmia in order to 
secure the well‑being of all animals.
Results: We found that serial injections increased the circulation time compared with single injections. Immediately 
after each injection, we observed a transitory drop in arterial pressure, a small drop in heart rate, and no episodes of 
arrhythmia. Although some cardiovascular effects were observed, they were transitory and easily recovered in both 
protocols.
Conclusions: These results indicate that the ACB system may be a valuable tool for in vivo, real‑time MNP monitoring 
that allows associations with other techniques, such as pulsatile arterial pressure and electrocardiogram recordings, 
helping ensuring the protocol safety, which is a fundamental step towards clinical applications.
Keywords: AC biosusceptometry, Magnetic nanoparticles, Circulation time, Pharmacokinetics, Cardiovascular 
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Background
Magnetic nanoparticles (MNPs) are known for their 
wide versatility in several applications fields [1]. Specifi-
cally regarding biomedical applications, they have been 
employed on cell detection and separation [2], stem 
cell tracking and signaling [3, 4] and also as therapeutic 
agents for hyperthermia [5–7] and drug delivery [8]. This 
broad range of possibilities is a unique factor that allows 
their application on both diagnosis and treatment, lead-
ing to multimodal applications [9, 10].
Preclinical characterization of nanoparticles is a crucial 
step towards clinical applications and, therefore, has gar-
nered great interest and efforts from the scientific com-
munity [11, 12]. The circulation time, or half-life (T1/2), of 
nanostructured agents is a parameter of major relevance 
for in vivo experimentation and clinical procedures [8, 9, 
13, 14]. Also, monitoring biodistribution, and clearance 
under in vivo conditions is of paramount importance in 
the field [15]. All these properties are mainly controlled 
by nanoparticles intrinsic properties, such as superficial 
charge, coating material, core and size, which influence 
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Pharmacokinetic modeling is the current gold stand-
ard method to assess T1/2 of nanoparticles. This approach 
is based upon sequential measurements of MNPs blood 
concentrations (i.e., ex  vivo studies) [16]. Although sev-
eral techniques have been employed for such purposes, 
such as electron spin resonance (ESR) [17, 18] or induc-
tively coupled plasma mass spectrometry (ICP-MS) [19, 
20], this method can only provide snapshots at specific 
time points.
Thus, developing proper detection methods that allow 
for in vivo studies and real-time monitoring is crucial in 
order to improve nanoparticles applicability and to ena-
ble real translational approaches [13, 21].
Among the current techniques, based on direct meas-
urements that allow in vivo particle detection, are mag-
netic resonance imaging (MRI) [13] and magnetic 
particle imaging (MPI) [22]. MRI presents some limita-
tions, specially distinguishing particle location within tis-
sue with low signal [23]. On other hand, the MPI system 
has shown great promise for nanoparticle detection and 
has already been reported to be able to track stem cells, 
within a 200 cells threshold (i.e., two orders of magnitude 
lower than the number of cells that can be detected by 
MRI) [23]. However, the use of MPI is currently limited 
to only a few scientists because of the complexity and 
high cost associated. Thus, there is still an urgent need 
to develop new simple and accessible techniques that can 
provide real-time information on MNP availability for 
in vivo applications.
The AC biosusceptometry (ACB) system is a biomag-
netic technique, already described and employed on 
pharmacological and gastrointestinal studies, in both 
animals and humans [24–26], and recently employed on 
magnetic nanoparticles detection [27]. When compared 
with similar detection systems, ACB is an accessible, ver-
satile, radiation-free and non-invasive technique with 
unique temporal resolution.
Another aspect that has drawn attention with regard to 
intravenous nanoparticle applications is the physiological 
effect of the administration protocol. The cardiovascular 
effects of intravenous MNP administration have been 
investigated [28, 29].
In order to achieve a real approach considering future 
clinical applications, it is necessary to find detection 
technologies that enable the association with standard 
methods to monitor physiological and, specifically, cardi-
ovascular parameters during the experimental procedure 
[30]. However, to the best of our knowledge, there are no 
studies focused on nanoparticle circulation time and the 
possible effects of MNP intravenous injections on cardio-
vascular parameters, simultaneously.
Thus, the purpose of our study was to apply the ACB 
device to monitor MNPs in the bloodstream, in vivo and 
in real-time, for two different administrations protocols, 
with simultaneous assessments on potential cardiovas-
cular effects, ensuring the safety of the procedure and 
decreasing the time and the number of animals employed 
in this kind of studies.
Methods
We performed a simultaneous, real-time evaluation of 
circulation time and cardiovascular parameters after 
intravenous injections of MNPs. We employed an ACB 
system to assess the circulation time of nanoparticles in 
the bloodstream and how it changes for different injec-
tions protocols. We simultaneously monitored mean 
arterial pressure (MAP), heart rate (HR), and cardiac 
electrical profile with the objective of ensuring the proce-
dure safety and also guaranteeing that all changes in cir-
culation time and nanoparticles availability were due to 
modifications in the injection protocol.
Magnetic nanoparticles
We employed a citrate coated, manganese ferrite nano-
particle (Cit-MnFe2O4), with physical core diameter of 
15 ±  5  nm, hydrodynamic diameter of 51.2  nm, super-
ficial charge of -27.8 mV and polydispersion index of the 
colloid sample of 0.21 in the stock solution with con-
centration of 45  mg/ml. The Fe and Mn content were 
found to be 74.4 ± 2.6 and 25.6 ± 2.6%, respectively. The 
3:1 ratio is related to a passivation process (see Addi-
tional file 1) that enriches the nanoparticle surface with 
Fe. The Cit-MNP was synthesized by co-precipitation 
method [5, 31] and presented a saturation magnetiza-
tion of 49.4 emu/g (247 emu/cm3), showing a quasi-static 
superparamagnetic behavior (i.e., the nanostructure did 
not present any coercive field under direct current (DC) 
conditions). The MNPs presented a hydrodynamic size 
increase when in contact with biological media (reach-
ing 110  nm approximately). All information concerning 
the nanoparticles synthesis and its physical and biologi-
cal characterization processes are described in the Addi-
tional file 1 (sections 1, 2).
AC biosusceptometry
The ACB system is a magnetic material detector that 
works as a double magnetic flux transformer, wherein the 
excitation/detection coil pair, farther from the magnetic 
material, acts as a reference (i.e. first order gradiometer 
configuration). When there is no magnetic material close 
to the measurement system, the signal response is mini-
mized. By closing the gap between the magnetic material 
and detection pair, an imbalance occurs in the magnetic 
flux, increasing the electrical signal acquired. This elec-
trical signal can be measured, digitized, and recorded 
online with the assistance of a sensitive-to-phase 
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amplifier (lock-in), analog/digital card, and a computer. 
The description and characterization of the system are 
detailed in the Additional file 1 (sections 3, 4).
Animal experimentation
We used 12 male rats (Rattus norvegicus albinus, Wistar), 
provided by Biotério Anilab (Paulínia, SP, Brazil), weigh-
ing 250–300 g. The animals were selected and maintained 
under suitable conditions with ad libitum feeding (ethics 
protocol CEUA–IBB 649). All of the animals underwent 
intraperitoneal urethane anesthesia (1.5 mg/kg), followed 
by femoral vein and artery cannulation, for intravenous 
MNPs administration and pulsatile arterial pressure 
(PAP) acquisition, respectively. For electrocardiography 
(ECG), the electrodes were inserted in the D2 derivation, 
and the ACB sensor was positioned over the animal’s car-
diac projection (Fig. 1).
Each animal received one or more doses of Cit-MNP, at 
a rate of 30 μl/s, according to their respective experimen-
tal group: G1 (six animals received three injections of 
300 μl of Cit-MNPs at 35 min intervals) and G2 (six ani-
mals received only one injection of 900 μl of Cit-MNPs.)
After MNP administration and online data acquisi-
tion (ACB, ECG, and PAP), we killed all of the animals 
by decapitation while they were still under anesthesia 
(90 min after the first MNP administration).
Acquisition and quantification
We performed online acquisition using a Lock-in ampli-
fier and Biopac system at a sampling rate of 200 Hz for all 
magnetic and electrical signals.
We assessed the pharmacokinetics parameters (i.e., 
MNP circulation time) employing two different methods: 
The T1/2 (half-life time) and the Mean Residence Time 
(MRT). To study the circulation time in each injec-
tion performed in G1 and in the sole injection in G2, 
we assess the circulation time in each animal by a single 
exponential decay and quantified it by a single-phase T1/2 
fitting model [8, 20, 32]. However, a T1/2 corresponding 
to the entire circulation time in G1 cannot be calculated 
by a single-phase fitting model, due to the signals’ shape 
(three peaks and their decays along signal). Thus, in order 
to compare both administration protocols, we employed 
a statistical moment approach. This strategy resulted in 
a MRT for each animal, which is calculated by the tem-
poral parameter weighted by the ACB intensity curve 
and normalized by the area under the curve. In this way, 
the MRT calculation takes into account the entire signal, 
regarding the three injections for G1 (three injections at a 
35 min interval between them, with total data acquisition 
period of 105 min), and one single injection for G2 (also 
with a 105 min of acquisition interval). The MRT calcula-
tion is a well described method widely used to assess the 
pharmacokinetics regarding multiple dosing regimens 
[33–35], and to quantify gastric emptying and gastroin-
testinal transit time [27, 36]. The MRT can be obtained 
according to Podczeck et al. [36]:
where It = ACB intensity signal at time t.
We also quantified the ACB signal intensity increase 
(IINC) after each injection performed in G1 and the injec-
tion in G2. To study the ACB reproducibility we summed 
all three IINC values obtained from G1 and compared with 
the IINC obtained in G2. The overall maximum intensity 
signal reached in each animal (IMAX), was also quanti-
fied. We also measured the MNP arrival time (TA) in the 
heart after systemic injections in both groups. TA is the 
time from the injection start until the signal reaches the 
IINC (e.g., its highest ACB signal intensity after each injec-
tion). See Additional file 1 for further details of the quan-
tification process (sections 4, 5).
For the cardiovascular analysis, we analyzed the RR 
interval (i.e., the regularity of repetitions of R waves on 
the electrocardiogram) to observe the possible presence 
of arrhythmias in the cardiac electrical profile of after 
intravenous MNP administration. We also assessed the 
effects of intravenous MNP administration on mean 
arterial pressure (MAP), heart rate (HR), which was 
calculated based on the PAP signal obtained. From the 
PAP signal, we also quantified the maximum hypoten-
sion instant (MHI) and the MAP recovery time, which 
is, respectively, the instant at which arterial pressure 










Fig. 1 Experimental setup for MNP administration and data acquisi‑
tion
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arterial pressure to return to baseline values. PAP, ECG, 
and ACB signals were registered and quantified using 
Aknowlodge 4.1.1, Matlab 2011and OriginPro 8 software.
Statistical analysis
All of the data was expressed as mean ± standard devia-
tion. For analyses of specific parameters under two dif-
ferent conditions in the same animal, we applied paired 
Student’s t tests. We used unpaired Student’s t test when 
we analyzed the same parameter in different animals. 
When evaluating a specific parameter that involved 
the same animals under three different conditions, we 
used one-way repeated-measures analysis of variance, 
followed by the Tukey post hoc test for comparisons 
between groups. Values of p < 0.05 were considered sta-
tistically significant.
Results
Magnetic nanoparticle monitoring by ACB system
We found a similar curve profile of the magnetic inten-
sity overtime in all of the animals after the MNP injec-
tions. Figure  2A shows a representative signal acquired 
in the G1 group, illustrating the magnetic peak intensity 
after each injection (IINC). Each signal showed a sharp 
peak immediately after the MNP injection, followed 
by exponential decay, which could be associated with 
the particles arriving in the heart and clearance from 
the bloodstream, respectively. Figure  2B shows a repre-
sentative signal acquired in the G2 group, illustrating the 
fitting curve that was applied to all of the data. Compari-
sons of each injection curve profile in the G1 group are 
illustrated in Fig. 2C. Note that the graphic scales, in both 
Fig.  2B, C, are different, wherein the intensities for G1 
group are considerably lower than in G2.
Figure 2 also describes how sequential particle admin-
istrations influenced the signal profile, in which the sec-
ond and third peaks resulted in a lower rate of signal 
decay, suggesting a reduction of the nanoparticles’ uptake 
pattern and a consequent increase in T1/2. Multiple injec-
tions also influenced the amount of circulating particles 
(residual intensity [IR]), indicating higher MNP availabil-
ity in the bloodstream after the latter injections.
Figure  3 presents the ACB signal intensity increase 
(IINC) detected in the G1 group after each MNP 
Fig. 2 Magnetic signal acquired by the ACB system. A Example of signal in the G1 group. B Signal acquired and fitting applied in the G2 group. C 
Fitting curves from each injection performed in the G1 group
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injection was not significantly different between injec-
tions (Fig. 3A). When we summed the intensity increase 
observed in all three injections and compared it with the 
results from the G2 protocol, the IINC were not signifi-
cantly different between groups, confirming that the ACB 
system detected a similar signal intensity increase when 
the particles concentration was the same, even after dif-
ferent injection protocols (Fig. 3B).
Figure  3C shows the IMAX reached in both protocols. 
In G1 group the maximum intensity was lower than the 
IMAX reached in G2, which was an expected outcome, 
since this protocol consisted of sequential injections, giv-
ing sufficient time for uptake mechanisms to remove part 
of the MNP from the circulation before its final injection, 
and consequential maximum concentration in the blood-
stream (IMAX), could be reached.
On regards to circulation time, the T1/2 significantly 
increased when we compared all injections (Fig.  4A). 
These results presented a linear trend (R2  =  0.78, 
p = 0.0001), confirming a relationship between sequen-
tial injections and T1/2, in which this parameter increased 
proportionally to each injection.
We found a T1/2 of 11.5  ±  3.5 min, 20.3  ±  2.1  min, 
and 24.7 ± 3.9 min for the first, second, and third injec-
tions, respectively, in the G1 group (Fig.  4A). The T1/2 
obtained for the single administration in G2 group was 
46.7  ±  4.3  min, which was statistically different from 
each administration in G1 group. Regarding circula-
tion time for the entire signal acquired, the comparison 
between protocols was performed over MRT calcula-
tions. We found a MRT of 64.0 ± 1.4 and 47.1 ± 3.6 min 
for the G1 and G2 groups, respectively (Fig. 4B), indicat-
ing a longer circulation time in multiple-dosing regimen 
compared with one sole injection.
The average TA for each administration in the G1 group 
was approximately 20 s, while the TA for G2 was 52 s, as 
shown in Table 1. Thus, in the G1 group, the 300 µl vol-
ume was injected after 10 s from the procedure start, tak-
ing approximately, another 10  s to reach the maximum 
signal increase. Since the injection rate was the same for 
both groups (30 µl/s), in G2 the 900 µl volume was com-
pletely injected after 30 s from the start, taking another 
20  s to reach the maximum signal increase. This delay 
Fig. 3 A IINC detected for each injection in G1. B Comparison of sum 
of IINC in G1 and IINC in G2. C Comparison of IMAX reached in each 
group. Different letters indicate significant differences between groups 
(p < 0.05)
Fig. 4 Magnetic nanoparticle T1/2. A T1/2 for each injection in G1. B Comparison of MRT obtained for each group. Different letters indicate significant 
differences between groups (p < 0.05)
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observed in G2, after the end of injection, may be caused 
by the greater volume injected, which obviously took a 
longer interval to arrive at the animals’ heart.
Cardiovascular evaluation
We found a transitory drop in MAP after the MNP injec-
tions in all of the animals. In G1, however, we observed 
a significantly greater pressure variation after the first 
injection compared with second and third injections, 
indicating a linear trend (p < 0.0001) and suggesting that 
sequential MNP injections cause smaller modifications of 
MAP compared with the first injection (Fig. 5A).
We compared arterial pressure before and after each 
MNP administration. We observed a 44 ±  4% decrease 
after the first injection in the G1 group (Fig.  5A and 
inset), followed by a 24 ± 9 and 22 ± 9% decrease after 
second and third injections, respectively. In the G2 
group, the MNP injection caused a 43 ± 6% drop in MAP 
(Fig. 5B, inset). Comparisons of the average pressure drop 
after the first injection in G1 and G2 revealed no signifi-
cant difference, indicating that the effects on MAP were 
not dose-dependent (Fig. 5B).
Table  2 shows a latter MHI after the first injection 
in the G1 group (77  ±  9  s), followed by shorter time 
intervals after second and third injections (16  ±  3 and 
17  ±  6  s, respectively), presenting a significant lin-
ear trend (R2  =  0.71, p  <  0.0001). The same compari-
son between the sole injection in the G2 group and first 
injection in the G1 group revealed no significant varia-
tion in MHI, also suggesting no MNP dose dependency.
The MAP recovery time was longest for the first injection 
(355 ± 85 s), followed by 41 ± 34 and 39 ± 30 s for second 
and third injections, respectively, indicating a significant 
decreasing linear trend (R2 = 0.68, p < 0.0001). The MAP 
recovery time was not significantly different between the 
first injection in G1 and sole injection in G2 (Table 2).
The heart rate monitoring, showed slight, but signifi-
cant, drop in frequency (p = 0.0184 in G1, p = 0.0003 in 
G2). The first MNP injection in G1 caused a 7 ± 5% drop 
in HR, while the MNP injection in G2 caused a 7 ± 2% 
drop in HR. Figure 6A presents the percentage variation 
in HR after the MNP injections in G1 and G2 groups. All 
data were compared using t tests, indicating that the first 
injection in G1 and sole injection in G2 diminished HR, 
differing significantly from zero value, whereas the sec-
ond and third injections in the G1 group did not influ-
ence HR (Fig. 6A). Also, analysis of the cardiac electrical 
profile revealed no significant arrhythmia events after the 
injections nor between first, second, and third injections 
(Fig. 6B and inset).
Discussion
In the present study, we employed the ACB system to 
monitor MNPs in the bloodstream in living animals in 
real time. Real-time monitoring and in vivo assessment of 
Table 1 MNPs time of arrival in animals’ heart
Different letters indicate significant differences between groups (p < 0.05)
TA (s)
G1
 1st injection 21.7 ± 9.8a
 2nd injection 19 ± 7.6a
 3rd injection 18.5 ± 6.3a
G2 51.5 ± 5.73b
Fig. 5 Effects of MNP administration on arterial pressure. A Percentage of MAP drop after each injection in G1. (Inset) Mean arterial pressure before 
and after the first injection in G1. B Percentage of MAP drop after the sole injection in G2. (Inset) Mean arterial pressure before and after the injection 
in G2. Different letters indicate significant differences between groups (p < 0.05)
Table 2 MHI and MAP recovery time
Different letters indicate significant differences between groups (p < 0.05)
MHI (s) MAP recovery time (s)
G1
 1st injection 77 ± 9a 355 ± 85a
 2nd injection 16 ± 3b 41 ± 34b
 3rd injection 17 ± 6b 39 ± 30b
G2 85 ± 17a 329 ± 33a
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nanoparticles remain a challenge that significantly ham-
pers their translational potential [21]. Several approaches 
have been employed on this task. Table  3 summarized 
some of these studies, the nanoparticle features and the 
detection technique employed on the circulation time 
assessment. Although Table 3 emphasizes the large vol-
ume of information and the importance of such studies, 
most of these techniques cannot be applied to in vivo nor 
real-time measurements. Thus, the possibility of deliver-
ing such features has drawn attention and is a crucial step 
to towards clinical applications [13, 21, 37].
Our ACB results revealed a similar magnetic inten-
sity curve pattern with regard to particle concentrations 
in all of the animals and for each MNP administration. 
Each injection caused a rapid peak signal intensity, which 
was related to the high blood concentration of magnetic 
material, followed by exponential decay, associated with 
the nanoparticle distribution within vascular compart-
ments and probably related with MNPs clearance from 
the bloodstream (Fig. 2).
The ACB system analysis demonstrated good repro-
ducibility and efficient data acquisition while monitor-
ing circulating MNPs in real time. The reproducibility 
was verified by comparing the IINC measured after each 
administration in two groups that received same doses 
of MNPs by different protocols. All of the IINC values 
recorded after each injection in G1 were similar. The sum 
of IINC for all three injections for each animal was not sig-
nificantly different from the G2 group, indicating a linear 
ACB signal response to particle concentrations in the 
bloodstream.
After the initial ACB signal peak that resulted from the 
MNP injections, we observed an intensity drop that can 
be attributed to distribution in the plasmatic compart-
ment and indirectly associated with particle uptake.
Since the final destination of nanoparticles within bio-
logical systems is a key aspect of their removal from the 
bloodstream and thus intrinsically related to circula-
tion time. The main retention and uptake processes are 
related to specific retention organs and inherent filtra-
tion, endocytosis, and metabolic function [15, 20]. These 
patterns, however, also depend on the shape, diameter, 
coating, and surface charge of nanoparticles, which influ-
ence uptake and the route of elimination. The average 
size of the MNPs that were used in the present study was 
within the 10-100  nm range. Magnetic nanoparticles of 
this size pass through discontinuous capillaries and are 
readily taken up by the reticuloendothelial system, mostly 
in the liver and spleen [11, 17, 38, 39].
Studies that are based on particle accumulation usually 
rely on circulation time to deduce uptake by biological 
processes, such as the EPR effect for tumor treatment [6, 
20] and angiography or liver imaging [40–42]. Nanopar-
ticles with a short T1/2 can be used as contrast agents for 
liver imaging, in which a shorter T1/2 decreases the time 
between nanoparticle administration and image acqui-
sition, thus making the procedure faster and reducing 
patient discomfort.
Many previous studies have reported the T1/2 for 
MNPs, ranging from a few minutes to several hours, 
depending on particle size and coating material (Table 3). 
As shown in Table 3, Liu et al. [19] and Huang et al. [20] 
reported a circulation time of around 2 h for polyethyl-
ene glycol (PEG)-coated nanoparticles, whereas Lacava 
et al. [18], Lacava et al. [16], and Jain et al. [13] reported 
a circulation time around 10  min for dextran-coated 
nanoparticles. The difference between those nanocarri-
ers might be related to the protein opsonization (Corona) 
effect [43]. Thus, the nanoparticle circulation time (T1/2) 
is an intrinsic property, strongly associated with their 
synthesis process and function.
With regard to the T1/2 values obtained, the citrate-
coated MNPs employed in this study were within the 
average values for particles with similar features. Our 
results revealed a positive linear relation between 
sequential MNP administrations and T1/2, suggesting a 
saturation pattern that interfered with the MNP uptake 
rate, which directly altered the nanoparticle circulation 
Fig. 6 Percent variation in HR and quantification of arrhythmia 
events after MNP administration. A Percent variation in HR measured 
after the first injection in G1 and after the sole injection in G2. (Inset) 
Variation in HR for each injection in G1. B Arrhythmia events quanti‑
fied before and after the first MNP injection in G1 and after the sole 
injection in G2. (Inset) number of arrhythmia events for each injection 
in G1
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time. In studies of multiple dosing protocols, once the 
administration frequency approximates the maximum 
elimination rate, the pharmacokinetic profile assumes a 
nonlinear behavior. In this case, the circulation time rises 
for the following administrations [44]. Since our injec-
tions interval were within minutes, considerably below 
the elimination process starting point, we obtained a 
nonlinear pharmacokinetic behavior. This behavior was 
proved by the increasing MNP circulation time obtained 
for second and third administrations in G1. The first 
300  µl injection in G1 resulted in a circulation time of 
approximately 12 min, while a single 900 µl injection in 
G2 resulted in a T1/2 of approximately 47 min, thus con-
firming the dose-dependent effect on T1/2, as described 
previously [40].
The comparison between the MRT value from all injec-
tions in G1 and the MRT from the sole injection in G2 
revealed a significant difference, indicating a longer MNP 
circulation time for sequential administrations. The MRT 
is an important parameter to quantify the permanence of 
the drug in the bloodstream following a multiple dosing 
regimen [33–36]. To the best of our knowledge, there are 
no studies that evaluated the influence of multiple dos-
ing protocols regarding MNP in the bloodstream, which 
is the most common protocol for drug administration. 
In general, this protocol was used to achieve the steady-
state (generally after more than three administrations) 
[45]. However, here we showed that multiple dosing pro-
tocols, even before achieving a steady-state, also prolong 
the permanence of the MNP in the bloodstream.
The shorter MRT in G2 might be some kind of pro-
cess initiated by a nanoparticle overdose, which may 
have triggered specific retention mechanisms that can 
increase MNP uptake from the bloodstream until sta-
ble values were reached. In this way, a protocol with the 
same dose, divided in three equal amounts, causes a pre-
vious saturation in the uptake process that increases the 
MNP circulation time. Following this rationale, the lack 
of previous saturation, associated with the rapid particles 
overload in G2, triggers a higher uptake rate by extravas-
cular compartments, thus promoting a faster MNP clear-
ance from the circulation. Our results suggest a saturated 
state, which was likely reached because of finite uptake 
levels by organs. Nonetheless, this difference in MRT 
between the G1 and G2 groups may help determine the 
appropriate administration protocol. Our results suggest 
that fractioned doses result in increased nanoparticles 
circulation time, while a single MNP dose may result in 
more circulating particles for a shorter period of time 
(Figs.  3, 4). This information may be very helpful, since 
Table 3 MNP characteristics, T1/2, species, dose, method and technique used in the study
n.a. information unavailable in original paper
Core/coat CD/HD (nm) T1/2 Species Dose Method/technique References
Maghemite/n.a. >40/n.a. <10 min n.a. n.a. n.a./n.a. [56]
Gd2O3/PVP 2.9/15.7 >12 min Mice n.a. In vivo/MRI (7T) (0.1 Hz) [37]
Magnetite/dextran 9.4/n.a. 10 min Mice n.a. Blood samples/ESR [18]
Ferumoxide/n.a. 4.3–6.2/19 3.7 h Rats 40 μmol Fe/kg Blood samples/gamma 
counter
[57]
KMnF3/PEG ‑10,000 18–23/n.a. 1.81 h Mice 20 mg/kg Blood samples/ICP‑MS [19]
Magnetite/PEG‑2000 11.3/23.8 2 h Mice 1.7 g Fe/kg Blood samples/ICP‑MS [20]
Iron oxide/dextran 5–15/120–180 6–19.8 min Human 15 µmg Fe/kg n.a./n.a. [58]
Iron oxide/n.a. n.a./80 12.8 ± 10.3 min Human 10–40 μmol/kg Blood samples/relaxometry [42]
NaYF4(Yb:Er)/PEG 180/220 4.75 ± 2.2 min Mice 5 mg/ml (200μl) Blood samples/ICP‑AES [59]
Iron oxide/oleic acid 15–25/210–250 31.2 min Mice 7 mg Fe/kg In vivo/MRI (9.4T) (0.1 Hz) [13]
Iron oxide/dextran 5–15/140 6.4 min Mice 7 mg Fe/kg In vivo/MRI (9.4T) (0.1 Hz) [13]
Magnetite/dextran 9.4/n.a. 6.9 ± 0.7 min Mice 4.9 ×1016 particles/ml 
(100 μl)
Blood samples/ESR [16]
Iron oxide/citrate 5/8 15 ± 2 min Rats 15 μmol Fe/kg In vivo/MRI (1.5T) (0.01 Hz) [40]
20 ± 3 min 30 μmol Fe/kg
29 ± 6 min 45 μmol Fe/kg
37 ± 5 min 60 μmol Fe/kg
61 ± 16 min 75 μmol Fe/kg
Magnetite/dimercaptosuc‑
cinic acid
12–15/n.a. 32 ± 6 Rats 10 mg Fe/kg Blood samples/ESR [60]
Iron oxide/dextran 30/n.a. 5.8 h Mice 10–20 mg Fe/kg In vivo/PET‑CT [61]
Iron oxide/PEG 7.1/20.3 143 min Mice 10 mg Fe/kg In vivo/PET‑CT [62]
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most of the studies attempt to improve the MNP circu-
lation time by changing the MNP conjugation and/or 
coating protocol. Here we demonstrate that changing 
the administration protocol may be a simple method to 
achieve this result.
With regard to the nanoparticle TA, we obtained con-
sistent and reproducible data, with a rise in the signal 
intensity immediately after the MNP injection, leading 
to an intensity peak (IINC), which suggests an increase 
in MNPs blood concentration, followed by a decay pro-
file, indicating the nanoparticles distribution in vascu-
lar compartment and its clearance from the circulation. 
These results, however, might be influenced by specific 
experimental conditions, such as different routes of 
administration.
Several studies have investigated the potential applica-
tion of MNPs as contrast agents for MRI [13, 40, 41] and 
as heat generators for hyperthermia [6, 11]. However, few 
studies have evaluated the cardiovascular effects caused 
by the MNPs administration. Additionally most of these 
have been performed using in vitro models and assessed 
isolated organs and arteries [46–48]. Furthermore, simul-
taneous assessments of cardiovascular parameters during 
the injection procedure are an important aspect towards 
clinical applications.
Our cardiovascular analysis revealed transitory hypo-
tension immediately after the MNP injections in both 
groups (Fig. 5A, B). The pressure drop observed after the 
first injection in G1 was statistically similar to G2, indi-
cating that hypotension episodes are not dose-depend-
ent. However, the sequential MNP injection protocol 
in G1 resulted in different MAP oscillations after each 
administration.
Mean arterial pressure depends on HR, systolic volume 
related to contractile cardiac force, and peripheral vascu-
lar resistance. We found a slight drop in HR after the first 
injection in G1 and after the sole injection in G2 (Fig. 6). 
Although significant, the variation was minimal (7%) 
compared with the drop in MAP (44%), suggesting that 
the main factor that influenced arterial pressure were 
reduction in peripheral vascular resistance and/or transi-
tory decrease in cardiac contractility.
The putative reduction in vascular resistance might 
be caused by shearing stress that results from contacts 
between MNPs and vessel walls or changes in blood 
viscosity, which can induce nitric oxide (NO) release by 
endothelial cells and cause vasodilation and consequent 
hypotension [49]. Changes in NO levels [50] or brady-
cardia episodes [46] have been reported after nanopar-
ticle administration. These studies described changes in 
NO levels that were caused by irreversible and deleteri-
ous cellular interactions [49], whereas the drop in HR 
did not significantly influence arterial pressure [46]. In 
the present study, we observed transitory and reversible 
modification of MAP, indicating that other parameters, 
beyond HR, more intensively influence arterial pressure, 
while the transitory pattern suggests no damage in the 
endothelium and in the contractile cardiac capacity. We 
observed significant differences in episodes of hypoten-
sion between the first and subsequent injections in G1 
(Table 2), which may be attributable to NO bioavailabil-
ity or other pressure regulatory elements in the system. 
Although we found some interesting information, inves-
tigating these physiological mechanisms is not the aim of 
this work and we can assume that more studies are nec-
essary to better elucidate these mechanisms.
The temporary pressure drop observed after MNP 
administration was reported previously by Iversen et  al. 
[29], who also found that peripheral vascular resistance is 
the main factor for MAP oscillations. Previous Phase I clin-
ical trials for citrate-coated iron oxide nanoparticles also 
reported a transitory drop in arterial pressure, in which this 
parameter returned to normal levels without any interven-
tion [51]. Although MNPs caused significant hypotension, 
this decrease in arterial pressure was transitory and can be 
easily controlled by vessel constrictor drugs.
Our assessment of the electrical cardiac profile did 
not show significant differences between pre- and post-
injection (Fig. 6). Acute cardiac arrhythmia is an urgent 
medical condition, which could limit the intravenous 
administration of nanoparticles. To our knowledge, very 
few studies have taken the caution to monitor the elec-
tric cardiac profile following intravenous administration 
of MNP [46]. The data on arrhythmia episodes (Fig. 6B, 
inset) did not show significant variations for any of the 
sequential MNP administrations. These data support the 
general notion that intravenous administration of MNPs 
does not cause any acute cardiovascular deleterious 
effects. Since the physiological changes were transitory, 
easily and rapidly recovered, we can assume that both 
protocols were safe from the cardiovascular aspect.
Concerning the safety protocols for MNP adminis-
tration, besides cardiovascular safety, we should draw 
attention to the Mn doses, since high doses may lead to 
manganism disease. Manganism is a neurodegenerative 
disorder and its symptoms are similar to Parkinson’s dis-
ease [52]. To avoid these problems, the Mn doses have 
to be lower than the neurotoxicity concentrations [8]. In 
rats, this dose is believed to be less than 93 mg/kg [53]. 
However, some studies indicate higher thresholds for safe 
protocols, specially regarding partitioned doses [50, 54]. 
In our case, we injected a total Mn dose of 32.8 mg/kg, 
which is very low compared to the dose limit to cause 
manganism. Also we did not notice any kind of a short-
term manganism symptom, and no animals died during 
the experiment.
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Conclusions
Although the present ACB system configuration presents 
limited spatial resolution compared with gold-standard 
imaging techniques, such as MRI and MPI, we could 
successfully assess the circulation time of MNP in the 
bloodstream. These results indicate that the ACB system 
may be an important tool for the in  vivo monitoring of 
MNP in real time, which might be combined with other 
techniques. Furthermore, the ACB system may allow the 
study of organ perfusion [55], biodistribution and tumor 
accumulation patterns to define time windows for both 
diagnostics and treatment modalities based on magnetic 
nanoparticles.
In summary, we employed an ACB system to detect 
MNPs in the bloodstream in living animals in real time. 
By monitoring MNPs in the bloodstream, we were able 
to determine circulation time in two different MNPs 
administration protocols. We observed transitory, 
although significant, cardiovascular alterations after 
MNP administration. The injections caused similar small 
and transitory changes in MAP and HR for both groups, 
without arrhythmia episodes, suggesting that intrave-
nous MNP administration is safe with regard to cardio-
vascular effects and does not influenced circulation time 
and accumulation patterns. Aiming clinical applications 
based on nano-agents, real-time monitoring of these 
clinical cardiovascular parameters is essential to ensure 
the protocol safety.
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